Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2019.12.18

Jay Stella

Jay Stella joins Sai Life Sciences as Chief Business Officer

Sai Life Sciences, one of India’s fastest growing Contract Development & Manufacturing Organizations (CDMOs), today announced the appointment of Jay Stella as Chief Business Officer, to lead the overall business development and program management for the company. Jay will be based out of Cambridge, Massachusetts, United States and report to the CEO & Managing Director, Krishna Kanumuri.

Jay Stella brings over 25 years of leadership in the pharmaceutical and medical devices industries with extensive experience across R&D, Manufacturing, Business Development, Finance, and Post-M&A Integrations. He held positions of increasing responsibility at Millennium Pharmaceuticals and Takeda Pharmaceuticals for 15 years, across strategy & operations, business development, and integrations & divestitures, while also gaining significant experience in the Japanese cultural and business environment. Earlier, he worked for medium sized biotech companies, Biogen and Genetics Institute, where he held various financial and operational roles. Prior to the pharmaceutical industry, Jay worked in technical operations, manufacturing, planning, and strategic sourcing roles in the medical device industry. Jay received his MBA from Boston University and his Baccalaureate degree from the University of Vermont in Spanish with minors in Chemistry and Biology.

Making the announcement, Krishna Kanumuri said, “Inducting top-notch global leadership and scientific talent is a key priority as part of our transformative effort, Sai Nxt. We are delighted to have Jay on board in this exciting phase.”

Sai Nxt is an organization-wide initiative aimed at transforming the company into a new generation CDMO. With investments of over US $ 150 million between 2019 and 2023, the transformation focus is on three key areas – People & culture, Processes & automation, Infrastructure & scientific capabilities.

Commenting on his appointment, Jay Stella said, “I am very excited to join Sai Life Sciences at this pivotal point in the company’s journey. Sai’s vision to support global innovators bring 25 new medicines to life by 2025 is an inspiring one, and I look forward to playing a part in achieving it.”

Share article

More News

2025.07.04

ISB professor talk

Exploring climate, water, plastic pollution & related stories: A fireside chat with ISB Prof. Anjal Prakash

To mark World Environment Day, Sai Life Sciences hosted an engaging fireside chat on June 6, 2025, with Dr. Anjal Prakash, Clinical Associate Professor at ISB and lead author on multiple IPCC reports. The session was designed not just to raise awareness but to spark deeper conversations around sustainability, public policy, and climate resilience. In […]
Read more

2025.06.17

Peptide research center

Sai Life Sciences’ Peptide Research Center gets featured in Lab Design News

Sai Life Sciences’ newly launched Peptide Research Center was featured in Lab Design News, offering insights into the design philosophy and intent behind the facility. The article showcases how the center brings together synthesis, purification, and conjugation under one roof, with a layout optimized for high-throughput workflows and seamless cross-functional collaboration. The feature also spotlighted […]
Read more

2025.05.22

Innovator companies prefer to work with integrated partners: Krishna Kanumuri

In a recent interview with Global Business Reports, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, highlighted a growing industry trend: innovator companies are increasingly seeking integrated partners who can support them seamlessly from discovery through development and manufacturing. As an end-to-end CRDMO in India, Sai Life Sciences is well-positioned to meet this […]
Read more

2025.05.14

Sai Life Sciences Limited reports robust FY25 results

Revenue grows by 16%; Net Profit up 105% year-on-year Sai Life Sciences Limited (BSE: 544306 I NSE: SAILIFE), an innovator focused, ContractResearch, Development and Manufacturing Organization (CRDMO) announced its financial results for the fourth quarter and full year ended March 31, 2025. Financial Performance: Particulars (₹ crores) FY25 FY24 YoY% Q4FY25 Q4FY24 YoY% Revenue from […]
Read more

2025.05.12

Sai Life Sciences wins Gold at CII Southern Region Awards

Sai Life Sciences has been honored with two Gold Awards at the CII Southern Region EHS Excellence Awards 2024, recognizing the company’s exemplary Environment, Health and Safety (EHS) initiatives across its sites in India. While the Integrated R&D Centre, Hyderabad, won Gold Award for EHS Excellence & Sector 2nd Topper in Pharmaceuticals & Healthcare, the […]
Read more